Emerald Advisers LLC Has $2.36 Million Stock Position in CeriBell, Inc. $CBLL

Emerald Advisers LLC grew its stake in CeriBell, Inc. (NASDAQ:CBLL) by 3.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 125,869 shares of the company’s stock after purchasing an additional 4,727 shares during the quarter. Emerald Advisers LLC owned about 0.35% of CeriBell worth $2,358,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. CenterBook Partners LP bought a new stake in shares of CeriBell in the 1st quarter valued at $3,531,000. New York State Common Retirement Fund bought a new stake in shares of CeriBell in the 1st quarter valued at $67,000. TimesSquare Capital Management LLC bought a new position in CeriBell during the 1st quarter worth about $10,312,000. Lord Abbett & CO. LLC increased its holdings in CeriBell by 7.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company’s stock worth $6,138,000 after purchasing an additional 23,451 shares in the last quarter. Finally, Swiss National Bank bought a new position in CeriBell during the 1st quarter worth about $467,000.

CeriBell Trading Down 6.2%

CeriBell stock opened at $12.03 on Thursday. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31. The stock has a market capitalization of $441.02 million and a P/E ratio of -4.02. The stock has a 50-day simple moving average of $12.10 and a 200 day simple moving average of $14.72.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%.The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. Analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Insider Activity

In other news, CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $12.54, for a total transaction of $139,344.48. Following the completion of the sale, the chief technology officer owned 167,704 shares in the company, valued at $2,103,008.16. The trade was a 6.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on CBLL. Raymond James Financial began coverage on CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and an average target price of $30.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.